PPARA and metabolic dysfunction-associated steatotic liver disease: Clinical trials have only shown modest effects of PPARα (fibrates) and PPARγ (thiazolidinediones and pioglitazone) agonists in reversing ART lipoatrophy [94,95], while other studies suggested these drugs may be useful in treating ART-associated diabetes and NAFLD [96].